{
  "id": 2888,
  "text": "745.Fabrini, M.G., et al.Clinical outcome of tailored adjuvant postoperative chemoradiotherapy in IB FIGO stage cervical cancer.Anticancer Res 29, 4205-4210 (2009).746.McCaffrey, R., et al.Neoadjuvant and adjuvant chemotherapy of cervical cancer: mature results of the phase 2 PBM-PFU protocol.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: 745.Fabrini, M.G., et al.Clinical outcome of tailored adjuvant postoperative chemoradiotherapy in IB FIGO stage cervical cancer.Anticancer Res 29, 4205-4210 (2009).746.McCaffrey, R., et al.Neoadjuvant and adjuvant chemotherapy of cervical cancer: mature results of the phase 2 PBM-PFU protocol.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "在IB期FIGO分期的宫颈癌中，术后辅助化放疗的个体化治疗被认为能够改善患者的临床预后。这种个体化治疗策略的主要优势在于根据患者的具体病情、肿瘤特征以及术后病理结果来定制治疗方案，从而更有效地抑制残留病灶，并降低癌症复发的风险。通过综合化疗和放疗的联合应用，可以增强治疗的疗效，提高生存率。此外，个体化治疗允许对治疗强度和方案进行精细调整，以达到最优疗效，同时尽可能减少对患者的副作用。这种方法不仅考虑到标准的治疗指南，同时也结合了患者个人的生物标志物和对治疗的反应，使得治疗更加精准和有效。",
  "query": "在IB期FIGO分期的宫颈癌中，术后辅助化放疗的个体化治疗如何影响临床预后？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在IB期FIGO分期的宫颈癌中，术后辅助化放疗的个体化治疗如何影响临床预后？\n\n<reference text>: 745.Fabrini, M.G., et al.Clinical outcome of tailored adjuvant postoperative chemoradiotherapy in IB FIGO stage cervical cancer.Anticancer Res 29, 4205-4210 (2009).746.McCaffrey, R., et al.Neoadjuvant and adjuvant chemotherapy of cervical cancer: mature results of the phase 2 PBM-PFU protocol.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "在IB期FIGO分期的宫颈癌中，术后辅助化放疗的个体化治疗被认为能够改善患者的临床预后。这种个体化治疗策略的主要优势在于根据患者的具体病情、肿瘤特征以及术后病理结果来定制治疗方案，从而更有效地抑制残留病灶，并降低癌症复发的风险。通过综合化疗和放疗的联合应用，可以增强治疗的疗效，提高生存率。此外，个体化治疗允许对治疗强度和方案进行精细调整，以达到最优疗效，同时尽可能减少对患者的副作用。这种方法不仅考虑到标准的治疗指南，同时也结合了患者个人的生物标志物和对治疗的反应，使得治疗更加精准和有效。"
}